Volitionrx LTD Form 4 insider transactions

Chief Commercial Officer Gael Forterre reports a transaction involving the withholding of shares to cover tax obligations related to restricted stock units.

Jacob Vincent Micallef, Chief Scientific Officer of VolitionRx, reports changes in beneficial ownership of company stock due to tax withholding obligations.

Nicholas Plummer, GC of Volition Diagnostics, reports the withholding of 1,497 common stock shares to cover tax obligations related to restricted stock units.

Rodney Gerard Rootsaert, Secretary of VolitionRx, reports the withholding of 4,158 common stock shares to cover tax obligations upon settlement of restricted stock units.

CEO Salvatore Thomas Butera disposed of 5,230 shares of VolitionRx common stock on September 28, 2024, to cover tax obligations related to the settlement of restricted stock units.

Ann-Louise Batchelor, Group Chief Marketing Officer of VolitionRx, reports the withholding of shares to cover tax obligations related to the settlement of restricted stock units.

Director Ethel Rubin acquired 15,000 restricted stock units in VolitionRX Ltd under the company's 2015 Stock Incentive Plan.

Nicholas Plummer, General Counsel of VolitionRx, reports acquiring 12,043 shares of common stock on September 1, 2024, as compensation in lieu of cash.

Gael Forterre, Chief Commercial Officer of VolitionRx Ltd, received 10,240 restricted stock units (RSUs) on September 1, 2024, in lieu of cash compensation.

Andrew Retter, Chief Medical Officer of VolitionRx Ltd, received 9,784 restricted stock units (RSUs) on September 1, 2024, in lieu of cash compensation.

Jasmine Kway, CEO Singapore Volition, received 15,668 restricted stock units (RSUs) from VolitionRx Ltd. in lieu of cash compensation on September 1, 2024.

Jacob Vincent Micallef, Chief Scientific Officer of VolitionRx Ltd, received 47,837 restricted stock units (RSUs) in lieu of cash compensation on September 1, 2024.

Director Guy Archibald Innes of VolitionRX Ltd. reports the acquisition of 18,342 restricted stock units (RSUs) in lieu of cash compensation, along with holdings through various trusts.

Gaetan Michel, Chief Operating Officer of VolitionRX Ltd, received 15,671 restricted stock units (RSUs) on September 1, 2024, in lieu of cash compensation.

Cameron John Reynolds, CEO of VolitionRx Ltd, was granted 103,243 restricted stock units (RSUs) on September 1, 2024, in lieu of cash compensation.

Director Alan Colman of VolitionRx Ltd. received 13,757 restricted stock units (RSUs) on September 1, 2024, in lieu of cash compensation.

Ann-Louise Batchelor, Group Chief Marketing Officer at VolitionRx, was granted 13,731 restricted stock units (RSUs) in lieu of cash compensation on September 1, 2024.

Terig Hughes, CFO of VolitionRX Ltd, received 13,493 restricted stock units (RSUs) on September 1, 2024, in lieu of cash compensation.

CEO of Volition Veterinary, Salvatore Thomas Butera, receives 35,783 restricted stock units (RSUs) in lieu of cash compensation and disposes of 99,350 jointly owned shares.

Rodney Gerard Rootsaert, Secretary of VolitionRX Ltd, received 15,258 restricted stock units (RSUs) on September 1, 2024, in lieu of cash compensation.

Director Phillip Barnes reports acquisition and disposal of VolitionRx Ltd (VNRX) common stock related to restricted stock units (RSUs) awarded in lieu of cash compensation.

Director Kim Nguyen acquired 9,171 shares of VolitionRX Ltd. in lieu of cash compensation on September 1, 2024.

Director Guy Archibald Innes of VolitionRX Ltd. recently purchased 150,000 shares of the company's common stock at $0.67 per share.

Director Kim Nguyen reports the vesting of 5,000 restricted stock units (RSUs) and the cancellation of 6,500 RSUs due to unmet performance goals.

Nicholas Plummer, GC of VolitionRx, reports the vesting of restricted stock units and cancellation of unvested units.

Director Phillip Barnes reports the vesting of 5,000 restricted stock units (RSUs) and cancellation of 6,500 RSUs in VolitionRx Ltd.

Ann-Louise Batchelor, Group Chief Marketing Officer at VolitionRX Ltd, reports changes in her beneficial ownership of company stock due to vesting of restricted stock units (RSUs) and cancellation of unvested RSUs.

Director Guy Archibald Innes acquired 5,000 shares of VolitionRx Ltd common stock through the vesting of restricted stock units, while also having 6,500 unvested RSUs cancelled.

Gael Forterre, Chief Commercial Officer of VolitionRx, reports acquisition of shares through RSU vesting and cancellation of unvested RSUs.

Jasmine Kway, CEO of Singapore VolitionRx, reports vesting of restricted stock units (RSUs) and cancellation of unvested RSUs.